Standard vs conformal radiation therapy for adenocarcinoma of the prostate: No difference

Prostate Cancer and Prostatic Diseases

Volumn 1, Issue 4, 1998, Pages 216-222

  Bean, J M ^a   Montana, G S ^a,b   Clough, R W ^a   King, S C ^a,b   Bentel, G C ^a   Marks, L B ^a   Anscher, M S ^a,c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Moore Regional Hospital   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000969043     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500236     Document Type: Article

References (19)

1. Hanks GE, Schultheiss TE, Hunt MA, Epstein B. Factors influencing incidence of acute grade 2 morbidity in conformal and standard radiation treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1995; 31: 25-29.
2. Soffen EM, Hanks GE, Hunt MA, Epstein BE. Conformal static field radiation therapy treatment of early prostate cancer versus non-conformal techniques: a reduction in acute morbidity. Int J Radiat Oncol Biol Phys 1992; 24: 485-488.
3. Vijayakumar S, Chen GTY. Implementation of three dimensional conformal radiation therapy: prospects, opportunities, and challenges. Int J Radiat Oncol Biol Phys 1995; 33: 979-983.
4. Corn BW et al. Conformal treatment of prostate cancer with improved targeting: superior prostate-specific antigen response compared to standard treatment. Int J Radiat Oncol Biol Phys 1995; 32: 325-330.
5. Sandler HM et al. Three dimensioinal conformal radiotherapy for the treatment of prostate cancer: low risk of chronic rectal morbidity observed in a large series of patients. Int J Radiat Oncol Biol Phys 1990; 18: 23-29.
6. Schultheiss TE, Hanks GE, Hunt MA, Lee WR. Incidence of and factors related to late complications in conformal and conventional radiation treatment of cancer of the prostate. Int J Radiat Oncol Biol Phys 1995; 32: 643-649.
7. Pollack A et al. Conventional vs. Conformal radiotherapy for prostatic cancer: preliminary results of dosimetry and acute toxicity. Int J Radiat Oncol Biol Phys 1996; 34: 555-564.
8. Yang FE et al. Acute toxicity in radiotherapy of prostate cancer: results of a randomized study with and without beam's-eye-view three-dimensional conformal therapy. Radiat Oncol Invest 1996; 4: 231-238.
9. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ. American Joint Committee on Cancer Manual for Staging of Cancer - Fourth Edition. J.B. Lippincott Company: Philadelphia, 1992, pp 181-186.
10. Bentel GC et al. The effectiveness of immobilization during prostate irradiation. Int J Radiat Oncol Biol Phys 1995; 31(1): 143-148.
11. Lawton CA et al. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys 1991; 21(4): 935-939.
12. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
13. Cox DR. Regression models and life tables. J R State Soc Ser B 1972; 34: 187-220.
14. Kavadi VS, Zagars GK, Pollack A. Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications. Int J Radiat Oncol Biol Phys 1994; 30(2): 279-287.
15. Zagars GK et al. The source of pretreatment serum prostate-specific antigen in clinically localized prostate cancer - T, N, or M? Int J Radiat Oncol Biol Phys 1995; 32(1): 21-32.
16. Hanks GE et al. Conformal technique dose escalation for prostate cancer: biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen ≥ 10 ng/ml. Int J Radiat Oncol Biol Phys 1996; 35(5): 861-868.
17. Hanks GE, Martz KL, Diamond JJ. The effect of dose on local control of prostate cancer. Int J Radiat Oncol Biol Phys 1988; 15(6): 1299-1305.
18. Pollack A, Zagars GK, Kopplin S. Radiotherapy and androgen ablation for clinically localized high-risk prostate cancer. Int J Radiat Oncol Biol Phys 1995; 32(1): 13-20.
19. Bolla M et al. Controlled clinical trial in high metastatic risk carcinoma of the prostate comparing pelvic radiotherapy alone to pelvic radiotherapy plus LHRH analogue. Int J Radiat Oncol Biol Phys 1996; 36(1): 227.